{"name":"Seres Therapeutics","slug":"seres","ticker":"MCRB","exchange":"NASDAQ","domain":"serestherapeutics.com","description":"David Berry is an American entrepreneur and business executive. He has co-founded Valo Health, Seres Therapeutics, Indigo Agriculture, Axcella Health, and contributed to the early development of Moderna.","hq":"Cambridge, MA","founded":0,"employees":"66","ceo":"Eric D. Shaff","sector":"Microbiome Therapeutics","stockPrice":8,"stockChange":0.24,"stockChangePercent":3.09,"marketCap":"$77M","metrics":{"revenue":1147000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-46899000,"cash":29834000,"dividendYield":0,"peRatio":-0.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"E cubaxasterone patent cliff ($0.0B at risk)","drug":"E cubaxasterone","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"SER-287 patent cliff ($0.0B at risk)","drug":"SER-287","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SER-109","genericName":"SER-109","slug":"ser-109","indication":"Recurrent Clostridioides difficile infection (rCDI) in adults","status":"phase_3"}]}],"pipeline":[{"name":"SER-109","genericName":"SER-109","slug":"ser-109","phase":"phase_3","mechanism":"SER-109 is a spore-based microbiome therapeutic that restores healthy gut bacterial composition to prevent recurrent Clostridioides difficile infection.","indications":["Recurrent Clostridioides difficile infection (rCDI) in adults"],"catalyst":""}],"recentEvents":[{"date":"2023-02-27","type":"regulatory","headline":"Seres Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for SER-262","summary":"Seres Therapeutics announced that the FDA has cleared the IND application for SER-262, a novel microbiome therapeutic for the treatment of Clostridioides difficile (C. diff) infection.","drugName":"SER-262","sentiment":"positive"},{"date":"2022-11-14","type":"earnings","headline":"Seres Therapeutics Reports Third Quarter 2022 Financial Results","summary":"Seres Therapeutics reported its third quarter 2022 financial results, including revenue of $13.4 million and a net loss of $44.8 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-01","type":"deal","headline":"Seres Therapeutics Enters into Collaboration and License Agreement with Pfizer","summary":"Seres Therapeutics announced that it has entered into a collaboration and license agreement with Pfizer to develop and commercialize SER-262 for the treatment of C. diff infection.","drugName":"SER-262","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE03WE1keUg3UHhrTEdpVDlnUnNtZmtLWlkxYklQb3plcGtQdGt3bHdZUGlmbmk5U1IzNk83UFlkZEFobW1IZktOdm5rX3JmRUJSWnQ0VXlybHdxSHpXMUlUdjhobnhTMGw4ZUs2S2NR?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Seres Therapeutics Inc (MCRB) - Stock Titan","headline":"If You Invested $1,000 in Seres Therapeutics Inc (MCRB)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNS015S0xCMmFVbUNzUVFMREZ3TjFBNW5id0xiZFFscFpLX0VPcXkwYXdUNE16WjdrNVlzRnI0YmlUWXV6eTZQVEZmRFpBeWNoUWJVeEVXWEx5dDdoRWxzY0tkdUdjVU9uUkdiRVFVYzlTb2paVlFzaE96dWxadUxPNkREdjlkb05NREl5Nkd5aWpYU3lFMGpJMHgyak04dTRaakpoVUFOSFJ3cWpRdTFWT09ZSUZqVGI1dUE?oc=5","date":"2026-03-02","type":"pipeline","source":"Stock Titan","summary":"New Seres boss backs microbiome drug to keep cancer patients on treatment - Stock Titan","headline":"New Seres boss backs microbiome drug to keep cancer patients on treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOcy0xXzVIV0JKQk05Q1JaSnlxWEFScUE0cVRadW5rNkcybUw3VGU4UXB5a3BGQVNFNXhUWUZVU1BpX242dWtVRmtBbV9EUG1WS2VMVlcxT1RKZFU4bzVFTTR5NzVIQUJzNmhRYVZ0STZkR3lkbC13NzRRWThjQlBpUUowMjRuWnpYODRpZHVVaE5PbWg1b2Q4LTJwYm1SNlJlZXVoNDB6a2lSb01obVpXYzh6aHBJSTA?oc=5","date":"2026-01-03","type":"pipeline","source":"AD HOC NEWS","summary":"Seres Therapeutics Stock: Speculative Biotech Turns Quiet After Roller-Coaster Year - AD HOC NEWS","headline":"Seres Therapeutics Stock: Speculative Biotech Turns Quiet After Roller-Coaster Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOTEFUbzVmLXUzZnR2T0FsOXFETkpqLW5kX3BPcVpucFo4dDhZX3JQcU5NSlU1a1JnSE9YR0hrbVA2OV9RM0dLZ1VkOWVTSFZrY2wtQkxEdU5sd1IxNWtrWlQxM1hLYUJYVHVzQzB3S0JCanZfb0JXaE5wZS1EX3BSY0RYS2pyTmZsS2VkMFIzZw?oc=5","date":"2025-11-05","type":"earnings","source":"Yahoo Finance","summary":"Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance","headline":"Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOaTFlRVh5QXNhZTNTam1LRmlFNTZtWUVGUDVxMTdPeUJ3empLVWx4M2dPTlVtX3pMOFkzRVczc1ZnNkNHYTdFaFJTUEp5S0c1dWFPUG1zTktzbXZnakkzXzFwWVVoTndZTE14UnNWUFNNNnBjS1BhazRZTkVMaUlMc2dWRENzVjByTVZibjNlbHJ1TWRjMVZLWDFiQS0wRDZXRU5sbjY3clpWa2lI?oc=5","date":"2025-07-29","type":"regulatory","source":"Seeking Alpha","summary":"Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough - Seeking Alpha","headline":"Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-20","type":"pipeline","source":"simplywall.st","summary":"individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st","headline":"individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQSjR6TVFlWk02b0hqT0hsMEFOUW9qVExFNnZNeW1uUXpVa0lRbS00bU5sbTBrWUhlMzNWWTE0TzBHNjM5NzAwVUxJbDZoajFWUGpYS3drTWZaS0pKMk4xZWppZEppZzFOOEVhSXVObFNwSkJQRk5uUWFydUI2RDZkRFluZmZBQ1EwcGxFLUhseFU1YUxEcWE4MlJxV1NKWEhBUDVfc085bVI1RU9I?oc=5","date":"2025-04-22","type":"pipeline","source":"Investing.com","summary":"Seres Therapeutics enacts 1-for-20 reverse stock split - Investing.com","headline":"Seres Therapeutics enacts 1-for-20 reverse stock split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNUTZtQzhUc0FTMU10WW9XYjFaT2tqVnBBbDFSVGJYUW1HVkt1YzctZHpnX0dBdVdyZlBmaG1IZldhM2RvX1puQlpKT2YyR0REZUlWbHkzcFdLdC1VVjNFVDZyNWpsMEhObHNRdXNValhBZ1RUVS1YOHUzWG1JSmVlWQ?oc=5","date":"2024-04-12","type":"pipeline","source":"MarketBeat","summary":"Top Skye Bioscience (SKYE) Competitors 2026 - MarketBeat","headline":"Top Skye Bioscience (SKYE) Competitors 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQbUg3ZDRVbWFUVGxFRGNZWkt5ZEctZkZlZlpuWkJCNUF2NGdma1gyZ1VKa3A1N0hfSzA1eDEzTGRGRDhzcHVkMS1ucnhNYTdYOWV6RHRLeGhIdmUtSHhSNy1ZSXR3VTFRRHYzTVNJWkJaaWZEWlNWTmpOWGdTWFFpNnp0VzNYMkhwSWN1MmdkcHhUUXZJZkVEUjF4eGFLNkpVaWROaHZZNm5OREtHb21hZWwxVEI1YkFSXy1zd05XaGc1UW5YLU1NV24zU2ZELUxFT2NJbjBVbkU?oc=5","date":"2023-04-26","type":"regulatory","source":"Reuters","summary":"US FDA approves Seres Therapeutics' pill for deadly C. difficile infections - Reuters","headline":"US FDA approves Seres Therapeutics' pill for deadly C. difficile infections","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNbUl1QmpFSjRua19ET3ljb0QwaDdDbkxFMGowLWZ5RElOUklUbnppc1czcGpQSGVwclU1N1RvUHZaSFVlZ0V3UWVTTXZOVUJVMVNFWXpLanhPbmo2NG0zeUxubFZEb3hUeGk2VDZ4S1lxR25yQnZKSHR1aHEzbkw0TFVqUjJFVGVmbEtFY3c1S2VEV0hhbmFlUVFFOA?oc=5","date":"2021-12-22","type":"pipeline","source":"Nasdaq","summary":"Top Biotechnology Indexes in the U.S. and How to Invest in Them - Nasdaq","headline":"Top Biotechnology Indexes in the U.S. and How to Invest in Them","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQVlBYT2RHSVQwajg0Sm1JZ3FWdGktbWh6R1YxUU94VkRLbjZJNnl4S3IwSEIxaUtiSnltMkYtem1kZUplU05EVDgycWR2MTBKRGZ0UWV1ZXpNNUFneHVkd0xMdWRDaG90LUUxYWI5Y3c2NGl1ay1rQ3NOQnhSZUt6TGxhcFhKRGJGR2NaUERQZ0Y3QUtocVdCMUNR?oc=5","date":"2019-03-11","type":"pipeline","source":"The Motley Fool","summary":"Here's Why Seres Therapeutics Stock Soared Today - The Motley Fool","headline":"Here's Why Seres Therapeutics Stock Soared Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOSVdTMHdoRk5qV0JqUm8tS1RicWladHRNeVh4RE1xZUlTN2VPR0pmS0I1eHYzWnF0aG5HSEY2MnBZQmt5MVd4MENjZUxfdkhCbnkzQXFSbWZZSUxFX010azIzbmtyVEw3ZkJTNFBXd3lEUGdmUWtPaUNaOGdOWkJQSC1DRlRheWgwbjRRaW13Z01yY3lnMkhwX293eE5DVXhV?oc=5","date":"2016-05-20","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders: Novartis bids farewell to Epstein with pharma split - Fierce Biotech","headline":"Chutes & Ladders: Novartis bids farewell to Epstein with pharma split","sentiment":"neutral"}],"patents":[{"drugName":"E cubaxasterone","drugSlug":"e-cubaxasterone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"SER-287","drugSlug":"ser-287","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Rebiotix","Ferring Pharmaceuticals","Merck & Co."],"therapeuticFocus":["Gastrointestinal diseases","Infectious diseases"],"financials":{"source":"yahoo_finance","revenue":789000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":789000},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"grossProfit":-5755000,"grossProfitHistory":[{"period":"2025-12-31","value":-5755000},{"period":"2024-12-31","value":-3532000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"rdSpend":49060000,"rdSpendHistory":[{"period":"2025-12-31","value":49060000},{"period":"2024-12-31","value":64600000},{"period":"2023-12-31","value":117597000},{"period":"2022-12-31","value":109651000}],"sgaSpend":39156000,"operatingIncome":-93971000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-93971000},{"period":"2024-12-31","value":-121315000},{"period":"2023-12-31","value":-195097000},{"period":"2022-12-31","value":-179914000}],"netIncome":5696000,"netIncomeHistory":[{"period":"2025-12-31","value":5696000},{"period":"2024-12-31","value":136000},{"period":"2023-12-31","value":-113724000},{"period":"2022-12-31","value":-250157000}],"eps":0.64,"epsHistory":[{"period":"2025-12-31","value":0.64},{"period":"2024-12-31","value":0},{"period":"2023-12-31","value":-17.77},{"period":"2022-12-31","value":-46.2}],"cash":45766000,"cashHistory":[{"period":"2025-12-31","value":45766000},{"period":"2024-12-31","value":30793000},{"period":"2023-12-31","value":127965000},{"period":"2022-12-31","value":163030000}],"totalAssets":138193000,"totalLiabilities":93975000,"totalDebt":82966000,"equity":44218000,"operatingCashflow":1117000,"operatingCashflowHistory":[{"period":"2025-12-31","value":1117000},{"period":"2024-12-31","value":-148609000},{"period":"2023-12-31","value":-117354000},{"period":"2022-12-31","value":-228816000}],"capex":-252000,"capexHistory":[{"period":"2025-12-31","value":-252000},{"period":"2024-12-31","value":-380000},{"period":"2023-12-31","value":-7975000},{"period":"2022-12-31","value":-9821000}],"freeCashflow":865000,"dividendsPaid":null,"buybacks":null,"employees":66,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":7539000,"ebit":80290000,"ebitda":81244000,"period":"2025-12-31","revenue":789000,"epsBasic":null,"netIncome":-15335000,"rdExpense":11684000,"epsDiluted":null,"grossProfit":197000,"operatingIncome":-19377000},{"sga":9476000,"ebit":-22477000,"ebitda":-21433000,"period":"2025-09-30","revenue":0,"epsBasic":0.94,"netIncome":8204000,"rdExpense":12616000,"epsDiluted":0.94,"grossProfit":-736000,"operatingIncome":-22477000},{"sga":10253000,"ebit":-19855000,"ebitda":-18796000,"period":"2025-06-30","revenue":0,"epsBasic":-2.27,"netIncome":-19855000,"rdExpense":12939000,"epsDiluted":-2.27,"grossProfit":-1689000,"operatingIncome":-24881000},{"sga":11888000,"ebit":32682000,"ebitda":33758000,"period":"2025-03-31","revenue":0,"epsBasic":3.76,"netIncome":32682000,"rdExpense":11821000,"epsDiluted":3.75,"grossProfit":-3527000,"operatingIncome":-27236000},{"sga":12462000,"ebit":-15637000,"ebitda":-14552000,"period":"2024-12-31","revenue":0,"epsBasic":null,"netIncome":-15637000,"rdExpense":12841000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-28835000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":11.63,"netIncome":null,"rdExpense":null,"epsDiluted":11.63,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8,"previousClose":7.76,"fiftyTwoWeekHigh":29.98,"fiftyTwoWeekLow":6.53,"fiftyTwoWeekRange":"6.53 - 29.98","fiftyDayAverage":8.51,"twoHundredDayAverage":14.26,"beta":0,"enterpriseValue":125812328,"forwardPE":-0.8,"priceToBook":1.73,"priceToSales":67.5,"enterpriseToRevenue":109.69,"enterpriseToEbitda":-1.5,"pegRatio":0,"ebitda":-83804000,"ebitdaMargin":0,"freeCashflow":-40485248,"operatingCashflow":-42153000,"totalDebt":80499000,"debtToEquity":303.8,"currentRatio":1.65,"returnOnAssets":-38.9,"returnOnEquity":-121.9,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":1,"targetMeanPrice":22,"targetHighPrice":22,"targetLowPrice":22,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.8,"institutionHeldPercent":26.3,"sharesOutstanding":9683934,"floatShares":7358337,"sharesShort":540750,"shortRatio":10.62,"shortPercentOfFloat":5.6,"epsTrailing":-5.2,"epsForward":-10.28,"revenuePerShare":0.13,"bookValue":4.63,"officers":[{"age":69,"name":"Mr. Richard N. Kender B.S., M.B.A.","title":"Interim CEO & Executive Chair"},{"age":50,"name":"Dr. Matthew R. Henn Ph.D.","title":"President & Chief Scientific Officer"},{"age":58,"name":"Ms. Marella  Thorell CPA","title":"Executive VP, CFO & Treasurer"},{"age":70,"name":"Mr. Thomas J. DesRosier Esq., J.D.","title":"Executive VP, Chief Legal Officer & Secretary"},{"age":41,"name":"Ms. Kelly  Brady M.S.","title":"Executive VP & COO"},{"age":null,"name":"Mr. Chris  McChalicher","title":"Executive VP & CTO"},{"age":null,"name":"Dr. Dennis M. Walling M.D.","title":"Senior VP of Clinical Development & Head of Clinical Research"},{"age":null,"name":"Ms. Ann  Kurowski","title":"Senior Vice President of Regulatory Affairs"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.serestherapeutics.com","phone":"617 945 9626"}}